DEA Proposes to Remove Opiate-Based Medication Naloxegol from Drug Schedule

The Drug Enforcement Administration (DEA) is proposing to remove the opiate-based medication naloxegol from the federal drug schedule, according to The Hill. The drug is currently considered a Schedule II drug under the Controlled Substances Act because it can be derived from opium alkaloids.

Other Schedule II drugs include heroin, methamphetamine, Adderall and Ritalin.

The Food and Drug Administration (FDA) approved nalexogol (Movantik) this fall for treatment of opioid-induced constipation in adults with chronic non-cancer pain. AstraZeneca, which makes naloxegol, submitted a petition seeking the drug’s removal from the drug schedule. The company stated the drug is not prone to abuse. In its proposal, the DEA agreed.

Full story of the removal of the opiate drug naloxegol at drugfree.org

Published by

Will Savage

Quantum Units Continuing Education provides online CEU training's to licensed professional mental health therapists, counselors, social workers and nurses. Our blog provides updates in the field of news and research related to mental health and substance abuse treatment.